Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Highlands Oncology Group, Springdale, Arkansas

Columbia University Irving Medical Center, New York, New York

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania